Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 3:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–496 of 496 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 0.9% Normal Saline (0.9% Sodium Chloride) injection Clear all

Conditions: Coronary Artery Disease
Interventions: Methylnaltrexone, Placebo, Morphine, Ticagrelor; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Solid Tumors, Adult
Interventions: HF158K1 / 1.4 g lipid dose, HF158K1 / 2.2 g lipid dose, HF158K1 / 2.9 g lipid dose; Drug
Lead sponsor: HighField Biopharmaceuticals Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Parkinson Disease, Depression
Interventions: OnabotulinumtoxinA, Control; Biological
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 95 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Abdominoplasty
Interventions: Botulinum Neurotoxin Serotype E, Placebo; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 23 Years to 55 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: Pasadena, California

Conditions: Traumatic Brain Injury
Interventions: TT301, Placebo; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Rib Fractures
Interventions: Ropivacaine, Normal Saline Flush, 0.9% Injectable Solution; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Tennis Elbow
Interventions: TenoMiR, 0.9% Sodium Chloride Injection; Drug
Lead sponsor: Causeway Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Redwood City, California • New York, New York

Conditions: Osteoarthritis of the Knee
Interventions: TLC599, DSP, Normal Saline; Drug · Other
Lead sponsor: Taiwan Liposome Company; Industry
Eligibility: 40 Years and older
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 41
States / cities: Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 33 more

Conditions: Schnitzler Syndrome, Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)
Interventions: 80 mg RPH-104, Placebo; Biological · Drug
Lead sponsor: R-Pharm Overseas, Inc.; Industry
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Denver, Colorado • Rochester, Minnesota • Portland, Oregon + 1 more

Conditions: Alzheimer Disease
Interventions: [11C]-Pittsburgh Compound B ([11C]PiB), F 18 AV-1451 (Flortaucipir); Drug
Lead sponsor: Tammie L. S. Benzinger, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Pain, Surgery, Regional Anesthesia
Interventions: Epidural, TAP Block; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Familial Hypoalphalipoproteinemia
Interventions: CER-001, Placebo; Drug
Lead sponsor: Cerenis Therapeutics, SA; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Traumatic Brain Injury
Interventions: Angiotensin (1-7), Sterile saline; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: HIV-1-infection
Interventions: 3BNC117-LS-J, 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3, Placebo; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 45 Years
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Seattle, Washington

Conditions: Healthy
Interventions: Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp), MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.], MVA-BN-Filo 5*10^7 Inf. U., Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 525 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: HIV Infection
Interventions: PGT121 3mg/kg IV, PGT121 10mg/kg IV, PGT121 30mg/kg IV, PGT121 3mg/kg SC, Placebo (0.9% Sodium Chloride Injection USP (Saline)); Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine

HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors

Trial of OnabotulinumtoxinA for Depression in Parkinson Disease

Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty

Effects of TT301 on Cytokine Levels Post Endotoxin Challenge

The Erector Spinae Plane Block and Its Effect on Respiratory Status and Pain Management in Rib Fracture Patients

Efficacy and Safety of TenoMiR in Lateral Epicondylitis

Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain

Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome

Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

Comparison of Epidural and TAP Block in Abdominal Surgery

CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases

Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults